Legend Biotech (Legend Biotech) Debt-to-Revenue : 1.03 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Legend Biotech Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Legend Biotech's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $3.2 Mil. Legend Biotech's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $325.5 Mil. Legend Biotech's annualized Revenue for the quarter that ended in Dec. 2023 was $317.9 Mil. Legend Biotech's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 1.03.

Legend Biotech Debt-to-Revenue Historical Data

The historical data trend for Legend Biotech's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Legend Biotech Debt-to-Revenue Chart

Legend Biotech Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.11

0.05

1.79

2.43

1.15

Legend Biotech Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															2.57	2.17	1.09	0.84	1.03

Competitive Comparison of Legend Biotech's Debt-to-Revenue

For the Biotechnology subindustry, Legend Biotech's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Legend Biotech's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Legend Biotech's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Legend Biotech's Debt-to-Revenue falls into.

Legend Biotech Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Legend Biotech's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.175	+	325.497)	/	285.143
	=	1.15

Legend Biotech's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(3.175	+	325.497)	/	317.856
	=	1.03

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2023) Revenue data.

Legend Biotech Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Legend Biotech's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Legend Biotech (Legend Biotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Legend Biotech Corp (NAS:LEGN) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

9LB:Germany

Address

2101 Cottontail Lane, Somerset, NJ, USA, 08873

Website

https://www.legendbiotech.com

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy is for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America.